Compare PRAX & EXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | EXP |
|---|---|---|
| Founded | 2015 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 7.0B |
| IPO Year | 2020 | 1994 |
| Metric | PRAX | EXP |
|---|---|---|
| Price | $364.58 | $202.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 9 |
| Target Price | ★ $572.13 | $227.11 |
| AVG Volume (30 Days) | 401.0K | ★ 435.8K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 0.49% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.29 |
| Revenue | N/A | ★ $495,023,000.00 |
| Revenue This Year | N/A | $1.97 |
| Revenue Next Year | $7,758.26 | $1.95 |
| P/E Ratio | ★ N/A | $62.73 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.25 | $171.99 |
| 52 Week High | $392.45 | $245.53 |
| Indicator | PRAX | EXP |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 43.88 |
| Support Level | $291.44 | $202.15 |
| Resistance Level | N/A | $223.21 |
| Average True Range (ATR) | 19.51 | 5.83 |
| MACD | 2.70 | -0.88 |
| Stochastic Oscillator | 76.31 | 17.16 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.